{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,13]],"date-time":"2026-09-13T09:05:29Z","timestamp":1789290329988,"version":"build-2803163510"},"reference-count":59,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T00:00:00Z","timestamp":1782950400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T00:00:00Z","timestamp":1782950400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BioDrugs"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1007\/s40259-026-00795-9","type":"journal-article","created":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T18:24:39Z","timestamp":1783016679000},"page":"869-882","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Ustekinumab Biosimilars versus Reference Ustekinumab for Moderate-to-Severe Plaque Psoriasis: A Pre-switch Systematic Review and Meta-analysis"],"prefix":"10.1007","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2355-2217","authenticated-orcid":false,"given":"Carlos Roberto","family":"Montes-de-Oca-Saucedo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Ghanem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Najwaa","family":"Kirmani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno","family":"Brice\u00f1o-Villardaga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea Michelle","family":"Talancon-Solana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adela Jatzari","family":"Salinas-Ocampo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grecia","family":"Sereno-Acevedo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adolfo","family":"Soto-Dom\u00ednguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raquel","family":"Rivera-D\u00edaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,2]]},"reference":[{"key":"795_CR1","doi-asserted-by":"publisher","DOI":"10.3390\/healthcare13192437","volume":"13","author":"D Li","year":"1990","unstructured":"Li D, Fan S, Song J, et al. Global psoriasis burden 1990-2021: evolving patterns and socio-demographic correlates in the global burden of disease 2021 update. Healthcare (Basel). 1990;13:2437. https:\/\/doi.org\/10.3390\/healthcare13192437.","journal-title":"Healthcare (Basel)"},{"key":"795_CR2","doi-asserted-by":"publisher","first-page":"1616","DOI":"10.1111\/jdv.14433","volume":"31","author":"G Girolomoni","year":"2017","unstructured":"Girolomoni G, Strohal R, Puig L, et al. The role of IL-23 and the IL-23\/TH17 immune axis in the pathogenesis and treatment of psoriasis. J Eur Acad Dermatol Venereol. 2017;31:1616\u201326. https:\/\/doi.org\/10.1111\/jdv.14433.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"795_CR3","doi-asserted-by":"publisher","first-page":"1665","DOI":"10.1016\/S0140-6736(08)60725-4","volume":"371","author":"CL Leonardi","year":"2008","unstructured":"Leonardi CL, Kimball AB, Papp KA, et al. Efficacy and safety of ustekinumab, a human interleukin-12\/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). Lancet. 2008;371:1665\u201374. https:\/\/doi.org\/10.1016\/S0140-6736(08)60725-4.","journal-title":"Lancet"},{"key":"795_CR4","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1016\/j.jaad.2018.11.057","volume":"80","author":"A Menter","year":"2019","unstructured":"Menter A, Strober BE, Kaplan DH, et al. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics. J Am Acad Dermatol. 2019;80:1029\u201372. https:\/\/doi.org\/10.1016\/j.jaad.2018.11.057.","journal-title":"J Am Acad Dermatol"},{"key":"795_CR5","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1080\/14712598.2020.1684472","volume":"20","author":"M Galluzzo","year":"2020","unstructured":"Galluzzo M, D\u2019Adamio S, Silvaggio D, et al. Ustekinumab treatment for moderate-to-severe plaque psoriasis: eight-year real-life experience. Expert Opin Biol Ther. 2020;20:95\u2013104. https:\/\/doi.org\/10.1080\/14712598.2020.1684472.","journal-title":"Expert Opin Biol Ther"},{"key":"795_CR6","doi-asserted-by":"publisher","first-page":"279","DOI":"10.3389\/fphar.2019.00279","volume":"10","author":"DC Baumgart","year":"2019","unstructured":"Baumgart DC, Misery L, Naeyaert S, Taylor PC. Biological therapies in immune-mediated inflammatory diseases: can biosimilars reduce access inequities? Front Pharmacol. 2019;10:279. https:\/\/doi.org\/10.3389\/fphar.2019.00279.","journal-title":"Front Pharmacol"},{"key":"795_CR7","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1007\/s40290-025-00578-7","volume":"39","author":"S Sinha","year":"2025","unstructured":"Sinha S, Raphael R. Developing biosimilars: challenges and opportunities. Pharm Med. 2025;39:341\u201352. https:\/\/doi.org\/10.1007\/s40290-025-00578-7.","journal-title":"Pharm Med"},{"key":"795_CR8","doi-asserted-by":"publisher","first-page":"407","DOI":"10.3390\/biologics4040025","volume":"4","author":"E Carmona-Rocha","year":"2024","unstructured":"Carmona-Rocha E, Puig L. Ustekinumab biosimilars. Biologics. 2024;4:407\u201322. https:\/\/doi.org\/10.3390\/biologics4040025.","journal-title":"Biologics"},{"key":"795_CR9","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1080\/14712598.2025.2508838","volume":"25","author":"JH Cheon","year":"2025","unstructured":"Cheon JH, Ye BD, Armuzzi A, et al. The \u201ctotality of evidence\u201d and \u201cextrapolation\u201d of SB17, a ustekinumab biosimilar. Expert Opin Biol Ther. 2025;25:615\u201332. https:\/\/doi.org\/10.1080\/14712598.2025.2508838.","journal-title":"Expert Opin Biol Ther"},{"key":"795_CR10","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1007\/s40259-023-00598-2","volume":"37","author":"K Klein","year":"2023","unstructured":"Klein K, Stolk P, De Bruin ML, Leufkens HGM, Crommelin DJA, De Vlieger JSB. The use of the term \u201cbiosimilar\u201d is misleading and may compromise patient safety. BioDrugs. 2023;37:235\u201345. https:\/\/doi.org\/10.1007\/s40259-023-00598-2.","journal-title":"BioDrugs"},{"key":"795_CR11","unstructured":"Food and Drug Administration. Scientific considerations in demonstrating biosimilarity to a reference product: guidance for industry. Silver Spring, MD: FDA; 2015. Accessed 28 Feb 2026."},{"key":"795_CR12","volume-title":"Guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: non-clinical and clinical issues","author":"European Medicines Agency","year":"2014","unstructured":"European Medicines Agency. Guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: non-clinical and clinical issues. Amsterdam: EMA; 2014."},{"key":"795_CR13","unstructured":"International Council for Harmonisation (ICH). ICH E9(R1) addendum on estimands and sensitivity analysis in clinical trials to the guideline on statistical principles for clinical trials. Geneva: ICH; 2019."},{"key":"795_CR14","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2023-076316","volume":"384","author":"BC Kahan","year":"2024","unstructured":"Kahan BC, Hindley J, Edwards M, Cro S, Morris TP. The estimands framework: a primer on the ICH E9(R1) addendum. BMJ. 2024;384:e076316. https:\/\/doi.org\/10.1136\/bmj-2023-076316.","journal-title":"BMJ"},{"key":"795_CR15","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0292231","volume":"18","author":"TM Herndon","year":"2023","unstructured":"Herndon TM, Ausin C, Brahme NN, et al. Safety outcomes when switching between biosimilars and reference biologics: a systematic review and meta-analysis. PLoS ONE. 2023;18:e0292231. https:\/\/doi.org\/10.1371\/journal.pone.0292231.","journal-title":"PLoS ONE"},{"key":"795_CR16","doi-asserted-by":"publisher","DOI":"10.3390\/ph18020243","volume":"18","author":"L Cen","year":"2025","unstructured":"Cen L, Arani R, Tang D. The role of outcome response rate in planning biosimilar studies using different evaluation metrics. Pharmaceuticals (Basel). 2025;18:243. https:\/\/doi.org\/10.3390\/ph18020243.","journal-title":"Pharmaceuticals (Basel)"},{"key":"795_CR17","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n160","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, Moher D, Bossuyt PM, et al. PRISMA 2020 explanation and elaboration: updated guidance and exemplars for reporting systematic reviews. BMJ. 2021;372:n160. https:\/\/doi.org\/10.1136\/bmj.n160.","journal-title":"BMJ"},{"key":"795_CR18","volume-title":"Cochrane handbook for systematic reviews of interventions, version 6.3","author":"JPT Higgins","year":"2022","unstructured":"Higgins JPT, Thomas J, Chandler J, et al. Cochrane handbook for systematic reviews of interventions, version 6.3. Cochrane; 2022."},{"key":"795_CR19","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1093\/bjd\/ljae402","volume":"192","author":"A Blauvelt","year":"2025","unstructured":"Blauvelt A, Papp K, Trivedi M, et al. Efficacy and safety of the ustekinumab biosimilar ABP 654 in patients with moderate-to-severe plaque psoriasis: a randomized double-blinded active-controlled comparative clinical study over 52 weeks. Br J Dermatol. 2025;192:826\u201336. https:\/\/doi.org\/10.1093\/bjd\/ljae402.","journal-title":"Br J Dermatol"},{"key":"795_CR20","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1080\/14712598.2025.2576506","volume":"25","author":"JC Szepietowski","year":"2025","unstructured":"Szepietowski JC, Reich A, Feldman SR, et al. Comparative efficacy and safety of biosimilar Bmab 1200 versus reference ustekinumab in moderate-to-severe plaque psoriasis: 52-week findings from the Phase 3 STELLAR-2 trial. Expert Opin Biol Ther. 2025;25:1121\u201333. https:\/\/doi.org\/10.1080\/14712598.2025.2576506.","journal-title":"Expert Opin Biol Ther"},{"key":"795_CR21","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1080\/14712598.2023.2235263","volume":"23","author":"SR Feldman","year":"2023","unstructured":"Feldman SR, Reznichenko N, Berti F, et al. Randomized, double-blind, multicenter study to evaluate efficacy, safety, tolerability, and immunogenicity between AVT04 and the reference product ustekinumab in patients with moderate-to-severe chronic plaque psoriasis. Expert Opin Biol Ther. 2023;23:759\u201371. https:\/\/doi.org\/10.1080\/14712598.2023.2235263.","journal-title":"Expert Opin Biol Ther"},{"key":"795_CR22","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1016\/j.jaad.2024.04.045","volume":"91","author":"SR Feldman","year":"2024","unstructured":"Feldman SR, Narbutt J, Girolomoni G, et al. A randomized, double-blind, phase III study assessing clinical similarity of SB17 (proposed ustekinumab biosimilar) to reference ustekinumab in subjects with moderate-to-severe plaque psoriasis. J Am Acad Dermatol. 2024;91:440\u20137. https:\/\/doi.org\/10.1016\/j.jaad.2024.04.045.","journal-title":"J Am Acad Dermatol"},{"key":"795_CR23","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1016\/j.jaad.2024.10.104","volume":"92","author":"X Man","year":"2025","unstructured":"Man X, Zaharieva K, Pulka G, et al. A randomized phase III study to compare efficacy and safety of BAT2206 (proposed ustekinumab biosimilar) with reference ustekinumab in patients with moderate to severe plaque psoriasis. J Am Acad Dermatol. 2025;92:724\u201331. https:\/\/doi.org\/10.1016\/j.jaad.2024.10.104.","journal-title":"J Am Acad Dermatol"},{"key":"795_CR24","doi-asserted-by":"publisher","first-page":"1448","DOI":"10.1016\/j.jaad.2025.08.005","volume":"93","author":"X Man","year":"2025","unstructured":"Man X, Zaharieva K, Pulka G, et al. A phase 3, randomized, double-blind, active-controlled clinical study to compare BAT2206, a ustekinumab biosimilar, with ustekinumab reference product in patients with moderate-to-severe psoriasis: treatment period 2 results. J Am Acad Dermatol. 2025;93:1448\u201355. https:\/\/doi.org\/10.1016\/j.jaad.2025.08.005.","journal-title":"J Am Acad Dermatol"},{"key":"795_CR25","doi-asserted-by":"publisher","first-page":"2135","DOI":"10.1007\/s12325-025-03138-2","volume":"42","author":"K Papp","year":"2025","unstructured":"Papp K, Balser S, Nopora K, et al. A randomised, double-blind trial to compare the efficacy, safety, and immunogenicity of the biosimilar ustekinumab FYB202 with reference ustekinumab in patients with moderate-to-severe plaque psoriasis. Adv Ther. 2025;42:2135\u201349. https:\/\/doi.org\/10.1007\/s12325-025-03138-2.","journal-title":"Adv Ther"},{"key":"795_CR26","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.jaad.2025.03.018","volume":"93","author":"L Xia","year":"2025","unstructured":"Xia L, Miao G, Yang X, et al. Efficacy and safety of SYSA1902 versus reference ustekinumab in moderate-to-severe plaque psoriasis: a multicenter, randomized, phase III study. J Am Acad Dermatol. 2025;93:115\u201323. https:\/\/doi.org\/10.1016\/j.jaad.2025.03.018.","journal-title":"J Am Acad Dermatol"},{"key":"795_CR27","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1007\/s40259-023-00630-5","volume":"38","author":"KA Papp","year":"2024","unstructured":"Papp KA, Lebwohl MG, Thaci D, et al. Efficacy and safety of candidate biosimilar CT-P43 versus originator ustekinumab in moderate to severe plaque psoriasis: 28-week results of a randomised, active-controlled, double-blind, phase III study. BioDrugs. 2024;38:121\u201331. https:\/\/doi.org\/10.1007\/s40259-023-00630-5.","journal-title":"BioDrugs"},{"key":"795_CR28","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/j.jdin.2025.09.004","volume":"24","author":"K Vekovska","year":"2025","unstructured":"Vekovska K, Imko-Walczuk B, Tichy M, et al. A randomized, double-blind, phase 3 study to compare efficacy, safety, and immunogenicity between DMB-3115 and reference product ustekinumab in patients with moderate-to-severe chronic plaque psoriasis. JAAD Int. 2025;24:147\u201365. https:\/\/doi.org\/10.1016\/j.jdin.2025.09.004.","journal-title":"JAAD Int"},{"key":"795_CR29","unstructured":"US Food and Drug Administration. Multi-Discipline Review (including Biosimilar Multidisciplinary Evaluation and Review [BMER]). Application nos. 761285Orig1s000; 761331Orig1s000. Silver Spring, MD: US Food and Drug Administration; 2023. Accessed Feb 2026."},{"key":"795_CR30","unstructured":"US Food and Drug Administration. Multi-Discipline Review (including BMER). Application no. 761343Orig1s000. Silver Spring, MD: US Food and Drug Administration; 2024. Accessed Feb 2026."},{"key":"795_CR31","unstructured":"US Food and Drug Administration. Multi-Discipline Review. Application nos. 761373Orig2s000; 761425Orig2s000. Silver Spring, MD: US Food and Drug Administration; 2024. Accessed Feb 2026."},{"key":"795_CR32","unstructured":"US Food and Drug Administration. Multi-Discipline Review. Application no. 761379Orig1s000. Silver Spring, MD: US Food and Drug Administration; 2024. Accessed Feb 2026."},{"key":"795_CR33","unstructured":"US Food and Drug Administration. Multi-Discipline Review. Application no. 761364Orig1s000. Silver Spring, MD: US Food and Drug Administration; 2024. Accessed Feb 2026."},{"key":"795_CR34","unstructured":"US Food and Drug Administration. Multi-Discipline Review. Application no. 761406Orig1s000. Silver Spring, MD: US Food and Drug Administration; 2025. Accessed Feb 2026."},{"key":"795_CR35","unstructured":"European Medicines Agency. CHMP assessment report. Procedure no. EMEA\/H\/C\/006467\/0000. Amsterdam: European Medicines Agency; 2025. Accessed Feb 2026."},{"key":"795_CR36","unstructured":"European Medicines Agency. CHMP assessment report. Procedure no. EMEA\/H\/C\/005918\/0000. Amsterdam: European Medicines Agency; 2024. Accessed Feb 2026."},{"key":"795_CR37","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1186\/s13643-016-0384-4","volume":"5","author":"M Ouzzani","year":"2016","unstructured":"Ouzzani M, Hammady H, Fedorowicz Z, Elmagarmid A. Rayyan-a web and mobile app for systematic reviews. Syst Rev. 2016;5:210. https:\/\/doi.org\/10.1186\/s13643-016-0384-4.","journal-title":"Syst Rev"},{"key":"795_CR38","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l4898","volume":"366","author":"JAC Sterne","year":"2019","unstructured":"Sterne JAC, Savovic J, Page MJ, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366:l4898. https:\/\/doi.org\/10.1136\/bmj.l4898.","journal-title":"BMJ"},{"key":"795_CR39","unstructured":"GRADEpro GDT: GRADEpro Guideline Development Tool [software]. McMaster University and Evidence Prime; 2026. Available from: gradepro.org."},{"key":"795_CR40","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1136\/ebmental-2019-300117","volume":"22","author":"S Balduzzi","year":"2019","unstructured":"Balduzzi S, Rucker G, Schwarzer G. How to perform a meta-analysis with R: a practical tutorial. Evid Based Ment Health. 2019;22:153\u201360. https:\/\/doi.org\/10.1136\/ebmental-2019-300117.","journal-title":"Evid Based Ment Health"},{"key":"795_CR41","doi-asserted-by":"publisher","first-page":"1","DOI":"10.18637\/jss.v036.i03","volume":"36","author":"W Viechtbauer","year":"2010","unstructured":"Viechtbauer W. Conducting meta-analyses in R with the metafor package. J Stat Softw. 2010;36:1\u201348. https:\/\/doi.org\/10.18637\/jss.v036.i03.","journal-title":"J Stat Softw"},{"key":"795_CR42","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/1471-2288-14-25","volume":"14","author":"J IntHout","year":"2014","unstructured":"IntHout J, Ioannidis JPA, Rovers MM, Goeman JJ. The Hartung-Knapp-Sidik-Jonkman method for random effects meta-analysis is straightforward and considerably outperforms the standard DerSimonian-Laird method. BMC Med Res Methodol. 2014;14:25. https:\/\/doi.org\/10.1186\/1471-2288-14-25.","journal-title":"BMC Med Res Methodol"},{"key":"795_CR43","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1186\/s12874-015-0091-1","volume":"15","author":"C Rover","year":"2015","unstructured":"Rover C, Knapp G, Friede T. Hartung-Knapp-Sidik-Jonkman approach and its modification for random-effects meta-analysis with few studies. BMC Med Res Methodol. 2015;15:99. https:\/\/doi.org\/10.1186\/s12874-015-0091-1.","journal-title":"BMC Med Res Methodol"},{"key":"795_CR44","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1111\/ajd.14138","volume":"64","author":"P Foley","year":"2023","unstructured":"Foley P, Gebauer K, Sullivan J, et al. Australian consensus: treatment goals for moderate to severe psoriasis in the era of targeted therapies-adult patients. Australas J Dermatol. 2023;64:476\u201387. https:\/\/doi.org\/10.1111\/ajd.14138.","journal-title":"Australas J Dermatol"},{"key":"795_CR45","doi-asserted-by":"publisher","DOI":"10.1111\/dth.15777","volume":"35","author":"J Yeung","year":"2022","unstructured":"Yeung J, Bourcier M, Gooderham MJ, et al. Management of moderate-to-severe plaque psoriasis with biologics: a treat-to-target position paper. Dermatol Ther. 2022;35:e15777. https:\/\/doi.org\/10.1111\/dth.15777.","journal-title":"Dermatol Ther"},{"issue":"Suppl 1","key":"795_CR46","doi-asserted-by":"publisher","first-page":"1","DOI":"10.23736\/S2784-8671.21.07132-2","volume":"157","author":"P Gisondi","year":"2022","unstructured":"Gisondi P, Fargnoli MC, Amerio P, et al. Italian adaptation of EuroGuiDerm guideline on the systemic treatment of chronic plaque psoriasis. Ital J Dermatol Venereol. 2022;157(Suppl 1):1\u201378. https:\/\/doi.org\/10.23736\/S2784-8671.21.07132-2.","journal-title":"Ital J Dermatol Venereol"},{"key":"795_CR47","doi-asserted-by":"publisher","first-page":"2841","DOI":"10.1007\/s13555-024-01261-6","volume":"14","author":"M Augustin","year":"2024","unstructured":"Augustin M, Gottlieb AB, Lebwohl M, et al. Complete skin clearance is associated with the greatest benefits to health-related quality of life and perceived symptoms for patients with psoriasis. Dermatol Ther (Heidelb). 2024;14:2841\u201357. https:\/\/doi.org\/10.1007\/s13555-024-01261-6.","journal-title":"Dermatol Ther (Heidelb)"},{"key":"795_CR48","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1111\/jdv.12817","volume":"29","author":"L Puig","year":"2015","unstructured":"Puig L. Pasi90 response: the new standard in therapeutic efficacy for psoriasis. J Eur Acad Dermatol Venereol. 2015;29:645\u20138. https:\/\/doi.org\/10.1111\/jdv.12817.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"795_CR49","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1007\/s13555-020-00475-8","volume":"11","author":"P Gisondi","year":"2021","unstructured":"Gisondi P, Talamonti M, Chiricozzi A, et al. Treat-to-target approach for the management of patients with moderate-to-severe plaque psoriasis: consensus recommendations. Dermatol Ther (Heidelb). 2021;11:235\u201352. https:\/\/doi.org\/10.1007\/s13555-020-00475-8.","journal-title":"Dermatol Ther (Heidelb)"},{"key":"795_CR50","doi-asserted-by":"publisher","first-page":"1158","DOI":"10.1111\/bjd.18333","volume":"182","author":"SK Mahil","year":"2019","unstructured":"Mahil SK, Wilson N, Dand N, et al. Psoriasis treat to target: defining outcomes in psoriasis using data from a real-world, population-based cohort study (BADBIR). Br J Dermatol. 2019;182:1158\u201366. https:\/\/doi.org\/10.1111\/bjd.18333.","journal-title":"Br J Dermatol"},{"key":"795_CR51","unstructured":"Food and Drug Administration. Scientific considerations in demonstrating biosimilarity to a reference product: updated recommendations for assessing the need for comparative efficacy studies. Draft guidance for industry. Silver Spring, MD: FDA; 2025."},{"key":"795_CR52","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1136\/conmed-2017-100007","volume":"1","author":"VF Azevedo","year":"2017","unstructured":"Azevedo VF. Considerations for an objective approach to biosimilarity. Consider Med. 2017;1:13\u20138. https:\/\/doi.org\/10.1136\/conmed-2017-100007.","journal-title":"Consider Med"},{"key":"795_CR53","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1007\/s40744-019-00190-7","volume":"7","author":"R Fleischmann","year":"2020","unstructured":"Fleischmann R, Stern R, Iqbal I. Implications of pharmacological and design differences across biosimilars and reference biologics. Rheumatol Ther. 2020;7:35\u201364. https:\/\/doi.org\/10.1007\/s40744-019-00190-7.","journal-title":"Rheumatol Ther"},{"key":"795_CR54","doi-asserted-by":"publisher","first-page":"4491","DOI":"10.1007\/s12325-020-01473-0","volume":"37","author":"BG Feagan","year":"2020","unstructured":"Feagan BG, Lam G, Ma C, Lichtenstein GR. Switching between biologics and biosimilars in IBD: considerations for clinicians. Adv Ther. 2020;37:4491\u2013518. https:\/\/doi.org\/10.1007\/s12325-020-01473-0.","journal-title":"Adv Ther"},{"key":"795_CR55","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1007\/s40259-017-0231-8","volume":"31","author":"V Strand","year":"2017","unstructured":"Strand V, Balsa A, Al-Saleh J, et al. Immunogenicity of biologics in chronic inflammatory diseases: a systematic review. BioDrugs. 2017;31:299\u2013316. https:\/\/doi.org\/10.1007\/s40259-017-0231-8.","journal-title":"BioDrugs"},{"key":"795_CR56","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1007\/s40259-025-00733-1","volume":"39","author":"M Schiestl","year":"2025","unstructured":"Schiestl M, Roy N, Trieb M, et al. Analytical data and single-dose PK are sufficient to conclude comparable immunogenicity for biosimilars: an ustekinumab case study. BioDrugs. 2025;39:769\u201376. https:\/\/doi.org\/10.1007\/s40259-025-00733-1.","journal-title":"BioDrugs"},{"key":"795_CR57","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.3109\/07388551.2015.1084266","volume":"36","author":"J Dumont","year":"2016","unstructured":"Dumont J, Euwart D, Mei B, Estes S, Kshirsagar R. Human cell lines for biopharmaceutical manufacturing: history, status, and future perspectives. Crit Rev Biotechnol. 2016;36:1110\u201322. https:\/\/doi.org\/10.3109\/07388551.2015.1084266.","journal-title":"Crit Rev Biotechnol"},{"key":"795_CR58","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1038\/nbt0896-975","volume":"14","author":"N Jenkins","year":"1996","unstructured":"Jenkins N, Parekh RB, James DC. Getting the glycosylation right: implications for the biotechnology industry. Nat Biotechnol. 1996;14:975\u201381. https:\/\/doi.org\/10.1038\/nbt0896-975.","journal-title":"Nat Biotechnol"},{"key":"795_CR59","doi-asserted-by":"publisher","first-page":"3395","DOI":"10.3390\/jcm12103395","volume":"12","author":"X Roblin","year":"2023","unstructured":"Roblin X, Duru G, Papamichael K, et al. Development of antibodies to ustekinumab is associated with loss of response in patients with inflammatory bowel disease. J Clin Med. 2023;12:3395. https:\/\/doi.org\/10.3390\/jcm12103395.","journal-title":"J Clin Med"}],"container-title":["BioDrugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40259-026-00795-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40259-026-00795-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40259-026-00795-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,13]],"date-time":"2026-09-13T09:02:44Z","timestamp":1789290164000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40259-026-00795-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,2]]},"references-count":59,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["795"],"URL":"https:\/\/doi.org\/10.1007\/s40259-026-00795-9","relation":{},"ISSN":["1173-8804","1179-190X"],"issn-type":[{"value":"1173-8804","type":"print"},{"value":"1179-190X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,2]]},"assertion":[{"value":"15 June 2026","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 July 2026","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that they have no conflicts of interest.","order":1,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethical approval was not required for this systematic review and meta-analysis of published studies.","order":2,"name":"Ethics","label":"Ethics Approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":3,"name":"Ethics","label":"Consent to Participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":4,"name":"Ethics","label":"Consent for Publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The extracted dataset will be made available by the corresponding author on reasonable request.","order":5,"name":"Ethics","label":"Availability of Data and Material","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The analytic code will be made available by the corresponding author on reasonable request.","order":6,"name":"Ethics","label":"Code Availability","group":{"name":"EthicsHeading","label":"Declarations"}}]}}